{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:52:13Z","timestamp":1791431533965,"version":"4.3.3"},"reference-count":61,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jval.2025.08.006","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T20:59:29Z","timestamp":1755809969000},"page":"46-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Generalized Risk-Adjusted Cost-Effectiveness Economic Model for Measuring the Value of Interventions That Delay Mobility Impairment Across Neurological Conditions"],"prefix":"10.1016","volume":"29","author":[{"given":"Jason","family":"Shafrin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaehong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Fajnor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyi-Sin","family":"Than","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth S.","family":"Mearns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey L.","family":"Kowal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Majda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub P.","family":"Hl\u00e1vka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jval.2025.08.006_bib1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jamaneurol.2020.4152","article-title":"Burden of neurological disorders across the US from 1990-2017: a global burden of disease study","volume":"78","author":"Feigin","year":"2021","journal-title":"JAMA Neurol"},{"issue":"10 suppl","key":"10.1016\/j.jval.2025.08.006_bib2","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.apmr.2011.01.025","article-title":"The neurology quality-of-life measurement initiative","volume":"92","author":"Cella","year":"2011","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.jval.2025.08.006_bib4","first-page":"87","article-title":"Neurological disorders","volume":"4","author":"Thakur","year":"2016","journal-title":"Dis Control Priorities"},{"issue":"11","key":"10.1016\/j.jval.2025.08.006_bib5","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S1474-4422(17)30299-5","article-title":"Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"16","author":"Feigin","year":"2017","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.jval.2025.08.006_bib6","doi-asserted-by":"crossref","first-page":"676","DOI":"10.3390\/brainsci13040676","article-title":"Challenges and perspectives of neurological disorders","volume":"13","author":"Ningrum","year":"2023","journal-title":"Brain Sci"},{"issue":"6","key":"10.1016\/j.jval.2025.08.006_bib7","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/01376517-200712000-00005","article-title":"Using focus groups to inform the Neuro-QOL measurement tool: exploring patient-centered, health-related quality of life concepts across neurological conditions","volume":"39","author":"Perez","year":"2007","journal-title":"J Neurosci Nurs"},{"issue":"14","key":"10.1016\/j.jval.2025.08.006_bib8","doi-asserted-by":"crossref","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS","volume":"26","author":"Walton","year":"2020","journal-title":"Mult Scler J"},{"issue":"2","key":"10.1016\/j.jval.2025.08.006_bib9","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.50.2.318","article-title":"Parkinsonism: onset, progression, and mortality","volume":"50","author":"Hoehn","year":"1998","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.jval.2025.08.006_bib11","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jval.2025.08.006_bib12","article-title":"Myasthenia gravis: a review","volume":"2012","author":"Jayam Trouth","year":"2012","journal-title":"Autoimmune Dis"},{"key":"10.1016\/j.jval.2025.08.006_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.690021","article-title":"Patient and payer preferences for additional value criteria","volume":"12","author":"Jakab","year":"2021","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.jval.2025.08.006_bib14","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jval.2019.10.014","article-title":"Health years in total: a new health objective function for cost-effectiveness analysis","volume":"23","author":"Basu","year":"2020","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.jval.2025.08.006_bib15","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jval.2017.12.007","article-title":"Defining elements of value in health care\u2014a health economics approach: an ISPOR Special Task Force report [3]","volume":"21","author":"Lakdawalla","year":"2018","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.jval.2025.08.006_bib16","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/hec.4236","article-title":"Sample restrictions and the elicitation of a constant willingness to pay per quality adjusted life year","volume":"30","author":"Nielsen","year":"2021","journal-title":"Health Econ"},{"issue":"3","key":"10.1016\/j.jval.2025.08.006_bib17","first-page":"633","article-title":"Measuring health burden without discriminating against the disabled","volume":"39","author":"Esposito","year":"2017","journal-title":"J Public Health"},{"key":"10.1016\/j.jval.2025.08.006_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhealeco.2020.102346","article-title":"Health technology assessment with risk aversion in health","volume":"72","author":"Lakdawalla","year":"2020","journal-title":"J Health Econ"},{"key":"10.1016\/j.jval.2025.08.006_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhealeco.2024.102857","article-title":"Risk preferences over health: empirical estimates and implications for medical decision-making","volume":"94","author":"Mulligan","year":"2024","journal-title":"J Health Econ"},{"issue":"10","key":"10.1016\/j.jval.2025.08.006_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140002","article-title":"Access to orphan drugs: a comprehensive review of legislations, regulations and policies in 35 countries","volume":"10","author":"Gammie","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jval.2025.08.006_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002191","article-title":"What is the purpose of the orphan drug act?","volume":"14","author":"Herder","year":"2017","journal-title":"PLoS Med"},{"issue":"6","key":"10.1016\/j.jval.2025.08.006_bib23","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.jval.2020.06.021","article-title":"Measuring the value healthy individuals place on generous insurance coverage of severe diseases: a stated preference survey of adults diagnosed with and without lung cancer","volume":"24","author":"Shafrin","year":"2021","journal-title":"Value Health"},{"issue":"6","key":"10.1016\/j.jval.2025.08.006_bib24","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jval.2023.03.014","article-title":"P1 quantifying the insurance and altruism value for rare diseases: A case study for Duchenne muscular dystrophy","volume":"26","author":"Shafrin","year":"2023","journal-title":"Value Health"},{"issue":"11","key":"10.1016\/j.jval.2025.08.006_bib25","first-page":"e368","article-title":"Reconsidering the economic value of multiple sclerosis therapies","volume":"22","author":"Liu","year":"2016","journal-title":"Am J Manag Care"},{"issue":"2","key":"10.1016\/j.jval.2025.08.006_bib26","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jval.2020.10.003","article-title":"Health technology assessment with diminishing returns to health: the generalized risk-adjusted cost-effectiveness (GRACE) approach","volume":"24","author":"Lakdawalla","year":"2021","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.jval.2025.08.006_bib27","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s10198-021-01367-0","article-title":"A guide to extending and implementing generalized risk-adjusted cost-effectiveness (GRACE)","volume":"23","author":"Lakdawalla","year":"2022","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.jval.2025.08.006_bib28","author":"Bayer"},{"issue":"7","key":"10.1016\/j.jval.2025.08.006_bib29","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"issue":"12","key":"10.1016\/j.jval.2025.08.006_bib30","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jval.2025.08.006_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577767","article-title":"Eculizumab treatment for myasthenia gravis subgroups: 2021 update","volume":"362","author":"Jiao","year":"2022","journal-title":"J Neuroimmunol"},{"issue":"7","key":"10.1016\/j.jval.2025.08.006_bib32","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/ner.12474","article-title":"Cost-effectiveness of deep brain stimulation for advanced Parkinson\u2019s disease in the United States","volume":"19","author":"Pietzsch","year":"2016","journal-title":"Neuromodulation Technol Neural Interface"},{"key":"10.1016\/j.jval.2025.08.006_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108085","article-title":"New hopes for disease modification in Parkinson\u2019s disease","volume":"171","author":"Poewe","year":"2020","journal-title":"Neuropharmacology"},{"issue":"10","key":"10.1016\/j.jval.2025.08.006_bib35","doi-asserted-by":"crossref","first-page":"841","DOI":"10.2165\/00023210-200822100-00005","article-title":"Cost effectiveness of pharmacotherapies in early Parkinson\u2019s disease","volume":"22","author":"Eggert","year":"2008","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.jval.2025.08.006_bib36","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s00415-013-7148-z","article-title":"The cost-effectiveness of deep brain stimulation in combination with best medical therapy, versus best medical therapy alone, in advanced Parkinson\u2019s disease","volume":"261","author":"Eggington","year":"2014","journal-title":"J Neurol"},{"key":"10.1016\/j.jval.2025.08.006_bib38","series-title":"Clinical if, review E. Siponimod for the Treatment of Secondary Progressive Multiple Sclerosis: Effectiveness and Value","year":"2019"},{"issue":"9884","key":"10.1016\/j.jval.2025.08.006_bib39","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/S0140-6736(12)62190-4","article-title":"Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial","volume":"381","author":"Gold","year":"2013","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jval.2025.08.006_bib40","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jval.2025.08.006_bib41","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/ene.13836","article-title":"EQUATION-5D-5L.and SF-6D health utility index scores in patients with myasthenia gravis","volume":"26","author":"Barnett","year":"2019","journal-title":"Eur J Neurol"},{"issue":"12","key":"10.1016\/j.jval.2025.08.006_bib42","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1177\/000313481207801224","article-title":"Evaluation of the new classification and surgical strategy for myasthenia gravis","volume":"78","author":"Cui","year":"2012","journal-title":"Am Surg"},{"issue":"11","key":"10.1016\/j.jval.2025.08.006_bib43","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1212\/WNL.0000000000002469","article-title":"Multiple sclerosis prevalence in the United States commercially insured population","volume":"86","author":"Dilokthornsakul","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.jval.2025.08.006_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2021.776847","article-title":"Global trends in the incidence, prevalence, and years lived with disability of Parkinson\u2019s disease in 204 countries\/territories from 1990 to 2019","volume":"9","author":"Ou","year":"2021","journal-title":"Front Public Health"},{"issue":"2","key":"10.1016\/j.jval.2025.08.006_bib45","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/mus.28006","article-title":"Incidence and prevalence of myasthenia gravis in the United States: a claims-based analysis","volume":"69","author":"Rodrigues","year":"2024","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.jval.2025.08.006_bib47","first-page":"101","article-title":"Long-term survival experience of patients with multiple sclerosis","volume":"29","author":"Pokorski","year":"1997","journal-title":"J Insur Med (N Y)"},{"issue":"1","key":"10.1016\/j.jval.2025.08.006_bib71","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/jnnp-2014-307791","article-title":"Modelling the natural history of primary progressive multiple sclerosis","volume":"86","author":"Harding","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"10.1016\/j.jval.2025.08.006_bib72","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1136\/jnnp-2016-315238","article-title":"Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study","volume":"88","author":"Lunde","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"10.1016\/j.jval.2025.08.006_bib73","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/mds.22875","article-title":"Progression of Parkinson\u2019s disease as evaluated by Hoehn and Yahr stage transition times","volume":"25","author":"Zhao","year":"2010","journal-title":"Mov Disord"},{"issue":"4","key":"10.1016\/j.jval.2025.08.006_bib49","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/ana.21867","article-title":"Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial","volume":"66","author":"Hawker","year":"2009","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.jval.2025.08.006_bib50","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jval.2025.08.006_bib51","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mus.26447","article-title":"Long-term safety and efficacy of eculizumab in generalized myasthenia gravis","volume":"60","author":"Muppidi","year":"2019","journal-title":"Muscle Nerve"},{"issue":"4","key":"10.1016\/j.jval.2025.08.006_bib52","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jval.2016.01.002","article-title":"Health utilities for multiple sclerosis","volume":"19","author":"Hawton","year":"2016","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.jval.2025.08.006_bib53","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1136\/jnnp.69.3.308","article-title":"What contributes to quality of life in patients with Parkinson\u2019s disease?","volume":"69","author":"Schrag","year":"2000","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"10.1016\/j.jval.2025.08.006_bib54","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1080\/13696998.2016.1194278","article-title":"Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective","volume":"19","author":"Jakubowiak","year":"2016","journal-title":"J Med Econ"},{"issue":"3","key":"10.1016\/j.jval.2025.08.006_bib59","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s40265-018-0875-9","article-title":"Eculizumab: a review in generalized myasthenia gravis","volume":"78","author":"Dhillon","year":"2018","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.jval.2025.08.006_bib60","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s40265-022-01678-3","article-title":"Efgartigimod: first approval","volume":"82","author":"Heo","year":"2022","journal-title":"Drugs"},{"issue":"10127","key":"10.1016\/j.jval.2025.08.006_bib61","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","article-title":"Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study","volume":"391","author":"Kappos","year":"2018","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.jval.2025.08.006_bib57","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s40273-013-0075-0","article-title":"Costs of Parkinson\u2019s disease in a privately insured population","volume":"31","author":"Johnson","year":"2013","journal-title":"Pharmacoeconomics"},{"issue":"11","key":"10.1016\/j.jval.2025.08.006_bib58","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1212\/01.wnl.0000218309.01322.5c","article-title":"Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States","volume":"66","author":"Kobelt","year":"2006","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jval.2025.08.006_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-6963-13-346","article-title":"A forgotten aspect of the NICE reference case: an observational study of the health related quality of life impact on caregivers of people with multiple sclerosis","volume":"13","author":"Acaster","year":"2013","journal-title":"BMC Health Serv Res"},{"issue":"3","key":"10.1016\/j.jval.2025.08.006_bib56","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/13696998.2018.1553179","article-title":"Cost-utility analysis of levodopa carbidopa intestinal gel (Duodopa) in the treatment of advanced Parkinson\u2019s disease in patients in Scotland and Wales","volume":"22","author":"Kalabina","year":"2019","journal-title":"J Med Econ"},{"issue":"9","key":"10.1016\/j.jval.2025.08.006_bib62","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s40273-023-01246-x","article-title":"Associating health-related quality-of-life score with time uses to inform productivity measures in cost-effectiveness analysis","volume":"41","author":"Jiao","year":"2023","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"10.1016\/j.jval.2025.08.006_bib64","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1177\/135245850000600409","article-title":"A quantitative study of unpaid caregiving in multiple sclerosis","volume":"6","author":"Carton","year":"2000","journal-title":"Mult Scler J"},{"issue":"5","key":"10.1016\/j.jval.2025.08.006_bib66","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jval.2024.03.001","article-title":"It is time to reconsider the 3% discount rate","volume":"27","author":"Cohen","year":"2024","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2025.08.006_bib67","series-title":"Forum for Health Economics and Policy, no. 0","article-title":"Two approaches for measuring treatment value under uncertainty: estimating insurance value and risk preferences in neurology","author":"Shafrin","year":"2025"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301525025227?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301525025227?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:12:41Z","timestamp":1791429161000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301525025227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1098301525025227"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2025.08.006","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Generalized Risk-Adjusted Cost-Effectiveness Economic Model for Measuring the Value of Interventions That Delay Mobility Impairment Across Neurological Conditions","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2025.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}